

Timothy A Yap

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3426964/publications.pdf>

Version: 2024-02-01

102
papers

11,206
citations

87888

38
h-index

36028

97
g-index

103
all docs

103
docs citations

103
times ranked

15654
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	1.9	1
2	A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. <i>Annual Review of Medicine</i> , 2022, 73, 231-250.	12.2	11
3	Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100456.	3.0	11
4	Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. <i>Cancer Discovery</i> , 2022, 12, 1542-1559.	9.4	17
5	IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin+paclitaxel, with or without bevacizumab in patients with advanced cancer. , 2022, 10, e003924.		8
6	First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. <i>Clinical Cancer Research</i> , 2022, 28, 3695-3708.	7.0	26
7	Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. <i>JAMA Network Open</i> , 2022, 5, e2213070.	5.9	21
8	Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. <i>Current Opinion in Oncology</i> , 2022, 34, 559-569.	2.4	6
9	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 80-91.	9.4	148
10	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277.	7.0	21
11	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	3.4	7
12	The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. <i>British Journal of Cancer</i> , 2021, 124, 857-859.	6.4	26
13	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	9.4	36
14	The promise of DNA damage response inhibitors for the treatment of glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab015.	0.7	16
15	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 298-301.	10.7	11
16	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3050-3060.	7.0	24
17	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	9.4	130
18	Precision Medicine in Oncology—Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. <i>JAMA Oncology</i> , 2021, 7, 507.	7.1	13

#	ARTICLE	IF	CITATIONS
19	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British Journal of Cancer, 2021, 125, 520-527.	6.4	37
20	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respiratory Medicine, 2021, 9, 613-621.	10.7	44
21	ATR Inhibition Induces CDK1-Dependent SPOC Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. Clinical Cancer Research, 2021, 27, 4898-4909.	7.0	66
22	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research, 2021, 27, 5213-5224.	7.0	53
23	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications, 2021, 12, 4626.	12.8	31
24	Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1825-1837.	1.8	11
25	Global Implementation of Precision Oncology. JCO Precision Oncology, 2021, 5, 854-858.	3.0	5
26	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.	2.4	26
27	Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 5572-5581.	0.9	75
28	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β 2 Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical Cancer Research, 2021, 27, 6666-6676.	7.0	27
29	Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer, 2021, 7, 930-957.	7.4	48
30	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends in Cancer, 2021, 7, 958-970.	7.4	18
31	DNA Damage Response. , 2021, , 1-12.		0
32	Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1517-1535.	0.7	9
33	DNA Damage Response. , 2021, , 536-547.		0
34	Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. Frontiers in Oncology, 2021, 11, 695936.	2.8	17
35	Development of Next-Generation Poly(ADP-Ribose) Polymerase Selective Inhibitors. Cancer Journal (Sudbury, Mass), 2021, 27, 521-528.	2.0	10
36	The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, 2020, 583, 807-812.	27.8	96

#	ARTICLE	IF	CITATIONS
37	Clinical <i>BRCA1/2</i> Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. <i>Cancer Discovery</i> , 2020, 10, 1475-1488.	9.4	109
38	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non- <i>BRCA1/2</i> -Mutant Cancers. <i>Cancer Discovery</i> , 2020, 10, 1528-1543.	9.4	82
39	Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. <i>Gynecologic Oncology</i> , 2020, 158, 570-575.	1.4	43
40	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3195-3204.	1.6	152
41	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
42	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 5951-5966.	8.2	72
43	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 157-164.	1.4	2
44	PARP inhibition â€” opportunities in pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 595-596.	27.6	19
45	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	7.0	110
46	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. <i>Cancer Cell</i> , 2019, 35, 851-867.e7.	16.8	156
47	The DNA Damaging Revolution: PARP Inhibitors and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 185-195.	3.8	144
48	PARP Inhibitors: Extending Benefit Beyond <i>BRCA</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3759-3771.	7.0	265
49	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. <i>Cancer Research</i> , 2019, 79, 311-319.	0.9	404
50	State-of-the-art strategies for targeting the DNA damage response in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 81-104.	27.6	736
51	Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3014-3014.	1.6	50
52	PIPA: A phase Ib study of selective 3'-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancersâ€”Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3087-3087.	1.6	4
53	Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2669-TPS2669.	1.6	10
54	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. <i>Clinical Cancer Research</i> , 2018, 24, 2719-2731.	7.0	54

#	ARTICLE	IF	CITATIONS
55	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. <i>Cancer Cell</i> , 2018, 33, 401-416.e8.	16.8	215
56	Precision oncology: East meets West. <i>International Journal of Cancer</i> , 2018, 142, 1734-1737.	5.1	1
57	Moving Precision Oncology Forward Amid Myths and Misconceptions. <i>JAMA Oncology</i> , 2018, 4, 1788.	7.1	2
58	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.9	155
59	Challenges with biomarkers in cancer drug discovery and development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 685-690.	5.0	28
60	Combination Drug Development in BRAF Mutant Colorectal Cancer. <i>Oncoscience</i> , 2018, 5, 51-53.	2.2	1
61	Circulating tumor DNA—From bench to bedside. <i>Current Problems in Cancer</i> , 2017, 41, 212-221.	2.0	2
62	Targeting ATR in cancer medicine. <i>Current Problems in Cancer</i> , 2017, 41, 302-315.	2.0	43
63	Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. <i>Cancer Discovery</i> , 2017, 7, 558-560.	9.4	25
64	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017, 77, 813-827.	10.9	42
65	Precision medicine in oncology. <i>Current Problems in Cancer</i> , 2017, 41, 163-165.	2.0	5
66	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. <i>Radiology</i> , 2017, 284, 88-99.	7.3	45
67	Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 20-37.	9.4	488
68	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. <i>Current Problems in Cancer</i> , 2017, 41, 111-124.	2.0	37
69	Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 12-14.	1.1	9
70	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	1.4	11
71	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6468-6477.	7.0	48
72	Development of Molecularly Driven Targeted Combination Strategies. <i>Oncologist</i> , 2017, 22, 1421-1423.	3.7	4

#	ARTICLE	IF	CITATIONS
73	Precision Medicine: Progress, Pitfalls, and Promises. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2641-2644.	4.1	7
74	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 70, 12-21.	2.8	36
75	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 25-40.	8.7	87
76	Combining Molecularly Targeted Agents: Is More Always Better?. <i>Clinical Cancer Research</i> , 2017, 23, 1123-1125.	7.0	6
77	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39.	2.6	18
78	Immuno-oncology combinations: raising the tail of the survival curve. <i>Cancer Biology and Medicine</i> , 2016, 13, 171-193.	3.0	98
79	Emerging strategies for the treatment of advanced small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E1249-E1253.	1.4	1
80	CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 697-699.	9.4	30
81	PARP inhibitors: the race is on. <i>British Journal of Cancer</i> , 2016, 114, 713-715.	6.4	135
82	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 60, 26-39.	2.8	28
83	Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 2431-2432.	1.6	6
84	A study of motivations and expectations of patients seen in phase 1 oncology clinics. <i>Cancer</i> , 2016, 122, 3501-3508.	4.1	24
85	Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792). <i>Cancer Research</i> , 2016, 76, CT012-CT012.	0.9	12
86	A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4203-4203.	1.4	15
87	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. <i>BMC Research Notes</i> , 2015, 8, 688.	1.4	4
88	Drugging PI3K in cancer: refining targets and therapeutic strategies. <i>Current Opinion in Pharmacology</i> , 2015, 23, 98-107.	3.5	186
89	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	7.0	171
90	Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity. <i>Molecular Cancer Therapeutics</i> , 2015, 14, PR14-PR14.	4.1	14

#	ARTICLE	IF	CITATIONS
91	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. <i>Clinical Cancer Research</i> , 2014, 20, 5672-5685.	7.0	66
92	Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 285.	0.7	30
93	Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways. <i>Journal of Clinical Oncology</i> , 2013, 31, 1592-1605.	1.6	249
94	Intratumor Heterogeneity: Seeing the Wood for the Trees. <i>Science Translational Medicine</i> , 2012, 4, 127ps10.	12.4	443
95	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 549-573.	9.4	96
96	PI3K&A€“AKT&A€“mTOR inhibitors for the systemic treatment of endometrial cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 421-430.	0.4	1
97	Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1293-1304.	4.1	23
98	Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 31-49.	329.8	178
99	Envisioning the future of early anticancer drug development. <i>Nature Reviews Cancer</i> , 2010, 10, 514-523.	28.4	262
100	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval. <i>Journal of Clinical Oncology</i> , 2010, 28, 2512-2519.	1.6	877
101	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from<i>BRCA</i>Mutation Carriers. <i>New England Journal of Medicine</i> , 2009, 361, 123-134.	27.0	3,312
102	Adjuvant Therapy of Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 120-130.	1.9	14